TG THERAPEUTICS, INC. Business Acquisition, Pro Forma Net Income (Loss)
TG THERAPEUTICS, INC. (TGTX) reported Business Acquisition, Pro Forma Net Income (Loss) of -$818.28 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2013-03-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2013-03-21
- TG THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2011-12-31 was -$789.27K.
- TG THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2011-09-30 was -$581.85K.
- TG THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2011-06-30 was -$3.28M.
- TG THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for fiscal 2011 was -$818.28K.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2011-12-31 | -$789.27K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | -$1.37M derived: sum of 2 quarters · filed 2013-03-21 | -$4.65M derived: sum of 3 quarters · filed 2013-03-21 | -$818.28K 10-K · filed 2013-03-21 |
| 2011-09-30 | -$581.85K 10-Q · filed 2012-11-14 | -$3.86M derived: sum of 2 quarters · filed 2012-11-14 | -$29.01K 10-Q · filed 2012-11-14 | |
| 2011-06-30 | -$3.28M 10-Q/A · filed 2012-09-07 | $552.84K 10-Q/A · filed 2012-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |